AstraZeneca, Daiichi aim for first pan-tumor ADC approval
Moderna leads development of mRNA vaccines in infectious diseases
BMS' subcutaneous Opdivo clears first phase 3 trial
Pfizer's layoff campaign ramps back up with dozens of SF-area cuts expected next month
